Abstract
Motility-related protein-1 (MRP-1/CD9) is involved in cell motility. We studied the change in the actin cytoskeleton, and the expression of actin-related protein (Arp) 2 and Arp3 and the Wiskott–Aldrich syndrome protein (WASP) family according to MRP-1/CD9 gene transduction into HT1080 cells. The frequency of cells with lamellipodia was significantly lower in MRP-1/CD9-transfected HT1080 cells than in control HT1080 cells (P<0.0001). MRP-1/CD9 gene transduction affected the subcellular localization of Arp2 and Arp3 proteins. Furthermore, MRP-1/CD9 gene transduction induced a downregulation of WAVE2 expression (P<0.0001). However, no difference was observed in the expression of Arp2, Arp3 or other WASPs. A neutralizing anti-MRP-1/CD9 monoclonal antibody inhibited downregulation of WAVE2 in MRP-1/CD9-transfected HT1080 cells (P<0.0001), and reversed the morphological effects of MRP-1/CD9 gene transduction. Furthermore, downregulation of WAVE2 by transfection of WAVE2-specific small interfering RNA (siRNA) mimicked the morphological effects of MRP-1/CD9 gene transduction and suppressed cell motility. However, transfection of each siRNA for Wnt1, Wnt2b1 or Wnt5a did not affect WAVE2 expression. Transfection of WAVE2-specific siRNA also did not affect expressions of these Wnts. These results indicate that MRP-1/CD9 regulates the actin cytoskeleton by downregulating of the WAVE2, through the Wnt-independent signal pathway.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout





Similar content being viewed by others
References
Bailly M, Macaluso F, Cammer M, Chan A, Segall JE, Condeelis JS . (1999). J Cell Biol 145: 331–345.
Berditchevski F, Odintsova E. . (1999). J Cell Biol 146: 477–492.
Charrin S, Le Naour F, Oualid M, Billard M, Faure G, Hanash SM et al. (2001). J Biol Chem 276: 14329–14337.
Chen HC, Appeddu PA, Isoda H, Guan JL . (1996). J Biol Chem 271: 26329–26334.
Condeelis JS, Wyckoff JB, Bailly M, Pestell R, Lawrence D, Backer J et al. (2001). Semin Cancer Biol 11: 119–128.
Eden S, Rohatgi R, Podtelejnikov AV, Mann M, Kirschner MW . (2002). Nature 418: 790–793.
Gutierrez-Lopez MD, Ovalle S, Yanez-Mo M, Sanchez-Sanchez N, Rubinstein E, Olmo N et al. (2003). J Biol Chem 278: 208–218.
Hall A . (1998). Science 279: 509–514.
Higashiyama M, Taki T, Ieki Y, Adachi M, Huang C, Koh T et al. (1995). Cancer Res 55: 6040–6044.
Huang C, Kohno N, Ogawa E, Adachi M, Taki T, Miyake M . (1998). Am J Pathol 153: 973–983.
Huang C, Liu D, Masuya D, Kameyama K, Nakashima T, Yokomise H et al. (2004). Oncogene 23: 7475–7483.
Ikeyama S, Koyama M, Yamaoko M, Sasada R, Miyake M . (1993). J Exp Med 177: 1231–1237.
King WG, Mattaliano MD, Chan TO, Tsichlis PN, Brugge JS . (1997). Mol Cell Biol 17: 4406–4418.
Kurisu S, Suetsugu S, Yamazaki D, Yamaguchi H, Takenawa T . (2005). Oncogene 24: 1309–1319.
Le Naour F, Charrin S, Labas V, Le Caer JP, Boucheix C, Rubinstein E . (2004). Cancer Immunol Immunother 53: 148–152.
Machesky LM, Mullins RD, Higgs HN, Kaiser DA, Blanchoin L, May RC et al. (1999). Proc Natl Acad Sci USA 96: 3739–3744.
Maekawa M, Ishizaki T, Boku S, Watanabe N, Fujita A, Iwamatsu A et al. (1999). Science 285: 895–898.
Miki H, Suetsugu S, Takenawa T . (1998). EMBO J 17: 6932–6941.
Miyake M, Koyama M, Seno M, Ikeyama S . (1991). J Exp Med 174: 1347–1354.
Miyake M, Inufusa H, Adachi M, Ishida H, Hashida H, Tokuhara T et al. (2000). Oncogene 19: 5221–5226.
Park KR, Inoue T, Ueda M, Hirano T, Higuchi T, Konishi I et al. (2000). Mol Hum Reprod 6: 719–725.
Rohatgi R, Ho HH, Kirschner MW . (2000). J Cell Biol 150: 1299–1309.
Soderling SH, Langeberg LK, Soderling JA, Davee SM, Simerly R, Raber J et al. (2003). Proc Natl Acad Sci USA 100: 1723–1728.
Stipp CS, Kolesnikova TV, Hemler ME . (2001). J Biol Chem 276: 40545–40554.
Suetsugu S, Yamazaki D, Kurisu S, Takenawa T . (2003). Dev Cell 5: 595–609.
Takenawa T, Miki H . (2001). J Cell Sci 114: 1801–1809.
Vartiainen MK, Machesky LM . (2004). Curr Opin Cell Biol 16: 174–181.
Yamaguchi H, Miki H, Suetsugu S, Ma L, Kirschner MW, Takenawa T . (2000). Proc Natl Acad Sci USA 97: 12631–12636.
Yamazaki D, Suetsugu S, Miki H, Kataoka Y, Nishikawa S, Fujiwara T et al. (2003). Nature 424: 452–456.
Yan C, Martinez-Quiles N, Eden S, Shibata T, Takeshima F, Shinkura R et al. (2003). EMBO J 22: 3602–3612.
Yauch RL, Hemler ME . (2000). Biochem J 351: 629–637.
Zhang XA, Bontrager AL, Hemler ME . (2001). J Biol Chem 276: 25005–25013.
Zhu B, Ping G, Shinohara Y, Zhang Y, Baba Y . (2005). Genomics 85: 657–665.
Zilber MT, Setterblad N, Vasselon T, Doliger C, Charron D, Mooney N et al. (2005). Blood 106: 3074–3081.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Huang, CL., Ueno, M., Liu, D. et al. MRP-1/CD9 gene transduction regulates the actin cytoskeleton through the downregulation of WAVE2. Oncogene 25, 6480–6488 (2006). https://doi.org/10.1038/sj.onc.1209654
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.onc.1209654
Keywords
This article is cited by
-
ITGA3 and ITGB4 expression biomarkers estimate the risks of locoregional and hematogenous dissemination of oral squamous cell carcinoma
BMC Cancer (2013)
-
Tetraspanins and tumor progression
Clinical & Experimental Metastasis (2011)
-
CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma
BMC Clinical Pathology (2009)
-
Tetraspanins: push and pull in suppressing and promoting metastasis
Nature Reviews Cancer (2009)